Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression
暂无分享,去创建一个
Weili Lin | Julia R Fielding | Joel S Parker | Yueh Lee | David S Lalush | Alexandra Arreola | Yueh Z. Lee | E. Wallen | D. Lalush | Weili Lin | J. Parker | W. Rathmell | J. Fielding | Alexandra Arreola | A. Khandani | M. Woods | M. I. Milowsky | S. Brooks | Eric M Wallen | W Kimryn Rathmell | Michael E Woods | Tiffany M. Sills | Samira A Brooks | Amir H Khandani | Tiffany Sills | Mathew I Milowsky | Angie B Smith | Mathew E Nielsen | M. E. Nielsen | Angela B. Smith | J. Parker
[1] R. Motzer,et al. Targeted therapy for metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[3] M. Remzi,et al. Rationale for percutaneous biopsy and histologic characterisation of renal tumours. , 2012, European urology.
[4] K. Junker,et al. A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. , 2011, The Journal of urology.
[5] M. Kattan,et al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. , 2014, European urology.
[6] Ciprian Catana,et al. PET/MRI for Neurologic Applications , 2012, The Journal of Nuclear Medicine.
[7] A. Drzezga,et al. First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses , 2012, The Journal of Nuclear Medicine.
[8] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.
[9] M. Reiser,et al. The role of functional imaging in the era of targeted therapy of renal cell carcinoma , 2014, World Journal of Urology.
[10] Gyan Bhanot,et al. Abstract 1996: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns , 2010 .
[11] R. Uzzo,et al. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. , 2011, Hematology/oncology clinics of North America.
[12] Robert G. Uzzo,et al. Heterogeneity and renal mass biopsy: a review of its role and reliability , 2014, Cancer biology & medicine.
[13] E. Wallen,et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. , 2012, European urology.
[14] P. A. Futreal,et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.
[15] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[16] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[17] P. Comoglio,et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.
[18] R. Motzer,et al. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling , 2014, Cancer medicine.
[19] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[20] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[21] Zoltan Szallasi,et al. Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers , 2014, European urology.
[22] C. Sternberg,et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[24] A. Hamid,et al. Targeted Therapy for Metastatic Renal Cell Carcinoma. , 2017, Acta medica Indonesiana.
[25] Rosamonde E Banks,et al. Renal cancer biomarkers: the promise of personalized care , 2012, BMC Medicine.
[26] H. Axelson,et al. Kidney cancer. , 2013, Seminars in cancer biology.
[27] C. Brinckerhoff,et al. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinoma , 2005, Oncogene.
[28] L. Gunaratnam,et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. , 2005, Cancer research.
[29] Brian Keith,et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. , 2008, Cancer cell.
[30] S. Yasuda,et al. Significance of 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT‐1) expression in the cancer , 2002, International journal of urology : official journal of the Japanese Urological Association.
[31] Lawrence A. Donehower,et al. The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.
[32] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[33] W. Rathmell,et al. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib , 2012, Nuclear medicine communications.
[34] S. Clifford,et al. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL‐independent pathway in clear cell renal tumourigenesis , 1998 .
[35] F. Waldman,et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.
[36] D. Appelbaum,et al. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer , 2013, Cancer medicine.
[37] J. Ochocki,et al. Fructose-1, 6-bisphosphatase opposes renal carcinoma progression , 2014, Nature.
[38] M. Uder,et al. Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[39] U. Tateishi,et al. Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report , 2010, BMC Cancer.